- Home
- OTLK vs CALC Comparison
OTLK vs CALC Comparison
Compare OTLK & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- CALC
- Stock Information
- Founded
- OTLK 2010
- CALC 2011
- Country
- OTLK United States
- CALC United States
- Employees
- OTLK N/A
- CALC N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- CALC Health Care
- Exchange
- OTLK Nasdaq
- CALC Nasdaq
- Market Cap
- OTLK 42.8M
- CALC 48.1M
- IPO Year
- OTLK 2016
- CALC N/A
- Fundamental
- Price
- OTLK $1.15
- CALC $3.38
- Analyst Decision
- OTLK Buy
- CALC Strong Buy
- Analyst Count
- OTLK 5
- CALC 2
- Target Price
- OTLK $5.25
- CALC $14.50
- AVG Volume (30 Days)
- OTLK 2.7M
- CALC 59.3K
- Earning Date
- OTLK 08-14-2025
- CALC 11-12-2025
- Dividend Yield
- OTLK N/A
- CALC N/A
- EPS Growth
- OTLK N/A
- CALC N/A
- EPS
- OTLK N/A
- CALC N/A
- Revenue
- OTLK $1,505,322.00
- CALC N/A
- Revenue This Year
- OTLK N/A
- CALC N/A
- Revenue Next Year
- OTLK $343.94
- CALC N/A
- P/E Ratio
- OTLK N/A
- CALC N/A
- Revenue Growth
- OTLK N/A
- CALC N/A
- 52 Week Low
- OTLK $0.79
- CALC $1.42
- 52 Week High
- OTLK $6.98
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- OTLK 46.22
- CALC 59.28
- Support Level
- OTLK $1.04
- CALC $3.02
- Resistance Level
- OTLK $1.13
- CALC $3.44
- Average True Range (ATR)
- OTLK 0.07
- CALC 0.19
- MACD
- OTLK 0.05
- CALC 0.01
- Stochastic Oscillator
- OTLK 84.91
- CALC 78.14
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.